Abstract:Objective: To elucidate potential molecular mechanisms differentiating osteoarthritis (OA) and rheumatoid arthritis (RA) through a bioinformatics analysis of differentially expressed genes (DEGs) in patient synovial cells, aiming to provide new insights for clinical treatment strategies. Materials and methods: Gene expression datasets GSE1919, GSE82107, and GSE77298 were downloaded from the Gene Expression Omnibus (GEO) database to serve as the training groups, with GSE55235 being used as the validation dataset. The OA and RA data from the GSE1919 dataset were merged with the standardized data from GSE82107 and GSE77298, followed by batch effect removal to obtain the merged datasets of differential expressed genes (DEGs) for OA and RA. Intersection analysis was conducted on the DEGs between the two conditions to identify commonly upregulated and downregulated DEGs. Enrichment analysis was then performed on these common co-expressed DEGs, and a protein-protein interaction (PPI) network was constructed to identify hub genes. These hub genes were further analyzed using the GENEMANIA online platform and subjected to enrichment analysis. Subsequent validation analysis was conducted using the GSE55235 dataset. Results: The analysis of differentially expressed genes in the synovial cells from patients with Osteoarthritis (OA) and Rheumatoid Arthritis (RA), compared to a control group (individuals without OA or RA), revealed significant changes in gene expression patterns. Specifically, the genes APOD, FASN, and SCD were observed to have lower expression levels in the synovial cells of both OA and RA patients, indicating downregulation within the pathological context of these diseases. In contrast, the SDC1 gene was found to be upregulated, displaying higher expression levels in the synovial cells of OA and RA patients compared to normal controls.Additionally, a noteworthy observation was the downregulation of the transcription factor PPARG in the synovial cells of patients with OA and RA. The decrease in expression levels of PPARG further validates the alteration in lipid metabolism and inflammatory processes associated with the pathogenesis of OA and RA. These findings underscore the significance of these genes and the transcription factor not only as biomarkers for differential diagnosis between OA and RA but also as potential targets for therapeutic interventions aimed at modulating their expression to counteract disease progression. Conclusion: The outcomes of this investigation reveal the existence of potentially shared molecular mechanisms within Osteoarthritis (OA) and Rheumatoid Arthritis (RA). The identification of APOD, FASN, SDC1, TNFSF11 as key target genes, along with their downstream transcription factor PPARG, highlights common potential factors implicated in both diseases. A deeper examination and exploration of these findings could pave the way for new candidate targets and directions in therapeutic research aimed at treating both OA and RA. This study underscores the significance of leveraging bioinformatics approaches to unravel complex disease mechanisms, offering a promising avenue for the development of more effective and targeted treatments.

Identification of therapeutic targets in osteoarthritis by combining heterogeneous transcriptional datasets, drug-induced expression profiles, and known drug-target interactions

Identification of biomarkers and potential drug targets in osteoarthritis based on bioinformatics analysis and mendelian randomization

Identification of novel drug targets for osteoarthritis by integrating genetics and proteomes from blood

Transcriptome regulation analysis in osteoarthritis primary tissues identifies high-confidence effector genes

Identification of transcription factors and construction of a novel miRNA regulatory network in primary osteoarthritis by integrated analysis

Identification of Novel Biomarkers and Candidate Small Molecule Drugs in Rheumatoid Arthritis and Osteoarthritis Based on Bioinformatics Analysis of High-Throughput Data.

Bioinformatic analysis combined with immune infiltration to explore osteoarthritis biomarkers and drug prediction

Identification of Pivotal Genes and Pathways in the Synovial Tissue of Patients with Rheumatoid Arthritis and Osteoarthritis Through Integrated Bioinformatic Analysis.

Identification and validation of hub genes and potential drugs involved in osteoarthritis through bioinformatics analysis

Combined Bioinformatics Analysis Reveals Gene Expression and DNA Methylation Patterns in Osteoarthritis.

Mendelian randomization based on genome-wide association studies and expression quantitative trait loci, predicting gene targets for the complexity of osteoarthritis as well as the clinical prognosis of the condition

Investigation of Candidate Genes for Osteoarthritis Based on Gene Expression Profiles.

Analysis of common differential gene expression in synovial cells of osteoarthritis and rheumatoid arthritis

Unveiling the bioinformatic genes and their involved regulatory mechanisms in type 2 diabetes combined with osteoarthritis

Identification of Potential Target Genes Associated with the Pathogenesis of Osteoarthritis Using Microarray Based Analysis.

Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis

Emerging therapeutic targets for osteoarthritis

Osteoarthritis: Insights into Diagnosis, Pathophysiology, Therapeutic Avenues, and the Potential of Natural Extracts

Data-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using interpretable machine learning

Unbiased transcriptome mapping and modeling identify candidate genes and compounds of osteoarthritis

Functional Annotation of Rheumatoid Arthritis and Osteoarthritis Associated Genes by Integrative Genome-Wide Gene Expression Profiling Analysis